Strategic Partnerships Secure and expand relationships with government healthcare buyers, leveraging recent DoD and VA supply contracts to pursue broader federal programs, military medical centers, and veterans’ healthcare networks for Hemastyl wound care solutions.

Department of Defense Target DoD and VA procurement channels for field deployments and pilots, highlighting Hemastyl's rapid wound closure data and neuropathy-focused peri-wound care to address battlefield and civilian orthopedic/diabetes-related wound needs.

Market Validation Position FDA-cleared Hemastyl as a validated option for high-risk chronic wounds, using the 95.5% closure rate across 22 high-risk wounds to differentiate from competitors and pursue hospital systems, large clinics, and rehabilitation networks.

Clinical Expansion Leverage the neuropathy and peri-wound care value proposition to expand into diabetes care networks, wound centers, and vascular clinics with pilot programs that demonstrate cost savings from reduced amputations and faster healing.

Rising Demand Capitalize on the growing medical device adoption by large healthcare payors and institutions, proposing bundled procurement and long-term supply agreements to scale Hemastyl across diverse U.S. healthcare systems.